Foto del docente

Andrea Ardizzoni

Professore ordinario

Dipartimento di Scienze Mediche e Chirurgiche

Settore scientifico disciplinare: MED/06 ONCOLOGIA MEDICA

Direttore Scuola di Specializzazione Oncologia Medica (DI 68/2015)

Pubblicazioni

Lo Preiato V.; Salvagni S.; Ricci C.; Ardizzoni A.; Pagotto U.; Pelusi C., Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature, «REVIEWS IN ENDOCRINE & METABOLIC DISORDERS», 2021, 22, pp. 337 - 349 [articolo]

Ciccarese F.; Piccinino A.; Brocchi S.; Balacchi C.; Dall'Olio F.G.; Massari F.; Rihawi K.; Paccapelo A.; Ardizzoni A.; Golfieri R., Expected and non-expected immune-related adverse events detectable by CT, «EUROPEAN JOURNAL OF RADIOLOGY», 2021, 138, Article number: 109617, pp. 1 - 7 [articolo]

Laprovitera N.; Salamon I.; Gelsomino F.; Porcellini E.; Riefolo M.; Garonzi M.; Tononi P.; Valente S.; Sabbioni S.; Fontana F.; Manaresi N.; D'Errico A.; Pantaleo M.A.; Ardizzoni A.; Ferracin M., Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches, «FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY», 2021, 9, Article number: 666156, pp. 1 - 15 [articolo]Open Access

Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco; Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna, IFN-γ and CD38 in Hyperprogressive Cancer Development, «CANCERS», 2021, 13, Article number: E309, pp. 1 - 24 [articolo]Open Access

Massari F.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Ardizzoni A.; Santoni M., Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials, «EUROPEAN JOURNAL OF CANCER», 2021, 154, pp. 120 - 127 [articolo]

Massari, Francesco; Rizzo, Alessandro; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Ardizzoni, Andrea; Santoni, Matteo, Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials, «EUROPEAN JOURNAL OF CANCER», 2021, 154, pp. 120 - 127 [articolo]

Comito F.; Nigro M.C.; Sperandi F.; Melotti B.; Ardizzoni A., Immunotherapy-refractory, EGFR overexpressing metastatic porocarcinoma responding to cetuximab, «EUROPEAN JOURNAL OF CANCER», 2021, 146, pp. 84 - 86 [articolo]

Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Rosellini M.; Marchetti A.; Montironi R.; Ardizzoni A.; Massari F., Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials, «EUROPEAN UROLOGY FOCUS», 2021, 1077, pp. 1 - 8 [articolo]

Rizzo, Alessandro; Mollica, Veronica; Giunchi, Francesca; Dall'Olio, Filippo Gustavo; Rosellini, Matteo; Marchetti, Andrea; Franceschini, Tania; Schiavina, Riccardo; Brunocilla, Eugenio; Fiorentino, Michelangelo; Ardizzoni, Andrea; Massari, Francesco, Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience, «PATHOLOGY RESEARCH AND PRACTICE», 2021, 220, Article number: 153410, pp. 1 - 5 [articolo]

Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor, Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, «VACCINES», 2021, 9, Article number: 19, pp. 1 - 13 [articolo]Open Access

Laprovitera N.; Riefolo M.; Porcellini E.; Durante G.; Garajova I.; Vasuri F.; Aigelsreiter A.; Dandachi N.; Benvenuto G.; Agostinis F.; Sabbioni S.; Berindan Neagoe I.; Romualdi C.; Ardizzoni A.; Trere' D.; Pichler M.; D'Errico A.; Ferracin M., MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary, «MOLECULAR ONCOLOGY», 2021, 15, pp. 2732 - 2751 [articolo]Open Access

Morgensztern D.; Dols M.C.; Ponce Aix S.; Postmus P.E.; Bennouna J.; Fischer J.R.; Juan-Vidal O.; Stewart D.J.; Ardizzoni A.; Bhore R.; Wolfsteiner M.; Reck M.; Talbot D.; Govindan R.; Ong T.J., nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+), «FRONTIERS IN ONCOLOGY», 2021, 10, Article number: 569715, pp. 1 - 9 [articolo]Open Access

Gelsomino F.; Facchinetti F.; Sisi M.; Zielli T.; Tiseo M.; Ardizzoni A., PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination, «IMMUNOTHERAPY», 2021, 13, pp. 363 - 369 [articolo]

Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A., PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors, «CLINICAL LUNG CANCER», 2021, 22, pp. 423 - 431 [articolo]

Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A., PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis, «FUTURE ONCOLOGY», 2021, 17, pp. 4415 - 4424 [articolo]